Aytu BioScience (AYTU) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $9. Rodman & Renshaw advised their investors in a research report released on Sep 26, 2016.
In a different news, on May 16, 2016, Joshua R. Disbrow (CEO) purchased 250,000 shares at $0.40 per share price. According to the SEC, on May 16, 2016, Jarrett Disbrow (COO) purchased 250,000 shares at $0.40 per share price. On May 16, 2016, Carl Dockery (director) purchased 5,000,000 shares at $0.40 per share price, according to the Form-4 filing with the securities and exchange commission.